Zoetis Inc. Class A

164.00-2.24-1.35%Vol 775.83K1Y Perf -15.56%
Mar 22nd, 2023 14:24 DELAYED
BID163.92 ASK164.06
Open165.39 Previous Close166.24
Pre-Market165.45 After-Market-
 -0.79 -0.48%  - -
Target Price
207.88 
Analyst Rating
Strong Buy 1.21
Potential %
26.50 
Finscreener Ranking
★★+     47.10
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     47.82
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     62.47
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★★     44.13
Price Range Ratio 52W %
51.64 
Earnings Rating
Sell
Market Cap76.00B 
Earnings Date
4th May 2023
Alpha0.01 Standard Deviation0.06
Beta0.73 

Today's Price Range

163.71165.94

52W Range

124.15201.32

5 Year PE Ratio Range

6.9018.20

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
1.63%
1 Month
-0.11%
3 Months
14.62%
6 Months
11.23%
1 Year
-15.56%
3 Years
64.69%
5 Years
102.58%
10 Years
413.22%

TickerPriceChg.Chg.%
ZTS164.00-2.2400-1.35
AAPL160.691.41000.89
GOOG105.990.15000.14
MSFT278.274.49301.64
XOM106.20-0.8400-0.78
WFC38.23-0.2500-0.65
JNJ152.77-1.1200-0.73
FB196.640.99000.51
GE91.87-0.3100-0.34
JPM129.81-0.7400-0.57
 
ProfitabilityValueIndustryS&P 500US Markets
70.00
34.80
40.50
28.40
27.33
RevenueValueIndustryS&P 500US Markets
6.04B
12.96
8.93
8.86
DividendsValueIndustryS&P 500US Markets
1.02
1.50
21.19
21.64
Payout ratio22.00
Earnings HistoryEstimateReportedSurprise %
Q04 20221.151.150.00
Q03 20221.241.21-2.42
Q02 20221.221.20-1.64
Q01 20221.221.328.20
Q04 20210.961.004.17
Q03 20211.101.2513.64
Q02 20211.081.1910.19
Q01 20211.041.2621.15
Earnings Per EndEstimateRevision %Trend
12/2022 QR1.15-5.74Negative
12/2022 FY4.87-2.40Negative
3/2023 QR1.38-4.17Negative
12/2023 FY5.37-4.28Negative
Next Report Date4th May 2023
Estimated EPS Next Report1.31
Estimates Count8
EPS Growth Next 5 Years %10.80
Volume Overview
Volume775.83K
Shares Outstanding463.39K
Shares Float470.35M
Trades Count20.13K
Dollar Volume127.73M
Avg. Volume2.11M
Avg. Weekly Volume2.31M
Avg. Monthly Volume1.95M
Avg. Quarterly Volume2.08M

Zoetis Inc. Class A (NYSE: ZTS) stock closed at 166.24 per share at the end of the most recent trading day (a 0.25% change compared to the prior day closing price) with a volume of 2.33M shares and market capitalization of 76.00B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 11300 people. Zoetis Inc. Class A CEO is Kristin C. Peck.

The one-year performance of Zoetis Inc. Class A stock is -15.56%, while year-to-date (YTD) performance is 13.44%. ZTS stock has a five-year performance of 102.58%. Its 52-week range is between 124.1483 and 201.32, which gives ZTS stock a 52-week price range ratio of 51.64%

Zoetis Inc. Class A currently has a PE ratio of 8.40, a price-to-book (PB) ratio of 14.76, a price-to-sale (PS) ratio of 11.35, a price to cashflow ratio of 37.70, a PEG ratio of 2.32, a ROA of 16.35%, a ROC of 18.35% and a ROE of 47.92%. The company’s profit margin is 27.33%, its EBITDA margin is 40.50%, and its revenue ttm is $6.04 Billion , which makes it $12.96 revenue per share.

Of the last four earnings reports from Zoetis Inc. Class A, there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $1.31 for the next earnings report. Zoetis Inc. Class A’s next earnings report date is 04th May 2023.

The consensus rating of Wall Street analysts for Zoetis Inc. Class A is Strong Buy (1.21), with a target price of $207.88, which is +26.50% compared to the current price. The earnings rating for Zoetis Inc. Class A stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Zoetis Inc. Class A has a dividend yield of 1.02% with a dividend per share of $1.50 and a payout ratio of 22.00%.

Zoetis Inc. Class A has a Buy technical analysis rating based on Technical Indicators (ADX : 8.97, ATR14 : 4.00, CCI20 : -10.67, Chaikin Money Flow : 0.10, MACD : -0.02, Money Flow Index : 67.12, ROC : -2.53, RSI : 50.96, STOCH (14,3) : 52.70, STOCH RSI : 1.00, UO : 57.52, Williams %R : -47.30), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Zoetis Inc. Class A in the last 12-months were: Gregory Norden (Option Excercise at a value of $0), Heidi C. Chen (Option Excercise at a value of $0), Jamie Brannan (Option Excercise at a value of $0), Kristin C. Peck (Option Excercise at a value of $363 206), Kristin C. Peck (Sold 10 000 shares of value $1 800 000 ), Linda Rhodes (Option Excercise at a value of $0), Louise M. Parent (Option Excercise at a value of $0), Michael B. McCallister (Option Excercise at a value of $0), Paul M. Bisaro (Option Excercise at a value of $0), Rimma Driscoll (Option Excercise at a value of $0), Robert J. Polzer (Option Excercise at a value of $150 605), Robert J. Polzer (Sold 1 120 shares of value $192 383 ), Roxanne Lagano (Option Excercise at a value of $1 730 996), Roxanne Lagano (Sold 21 678 shares of value $3 813 630 ), Wafaa Mamilli (Option Excercise at a value of $0), Willie M. Reed (Option Excercise at a value of $0), Willie M. Reed (Sold 1 855 shares of value $301 085 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (83.33 %)
9 (81.82 %)
9 (81.82 %)
Moderate Buy
1 (8.33 %)
1 (9.09 %)
1 (9.09 %)
Hold
1 (8.33 %)
1 (9.09 %)
1 (9.09 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.21
Strong Buy
1.23
Strong Buy
1.23

Zoetis Inc. Class A

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

CEO: Kristin C. Peck

Telephone: +1 973 822-7000

Address: 10 Sylvan Way, Parsippany 07054, NJ, US

Number of employees: 11 300

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

56%44%

Bearish Bullish

57%43%


News

Stocktwits